BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1570 related articles for article (PubMed ID: 30774737)

  • 21. Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.
    Mis MSC; Brajkovic S; Tafuri F; Bresolin N; Comi GP; Corti S
    Mol Neurobiol; 2017 Aug; 54(6):4466-4476. PubMed ID: 27349438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS.
    Gendron TF; Bieniek KF; Zhang YJ; Jansen-West K; Ash PE; Caulfield T; Daughrity L; Dunmore JH; Castanedes-Casey M; Chew J; Cosio DM; van Blitterswijk M; Lee WC; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
    Acta Neuropathol; 2013 Dec; 126(6):829-44. PubMed ID: 24129584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.
    Simón-Sánchez J; Dopper EG; Cohn-Hokke PE; Hukema RK; Nicolaou N; Seelaar H; de Graaf JR; de Koning I; van Schoor NM; Deeg DJ; Smits M; Raaphorst J; van den Berg LH; Schelhaas HJ; De Die-Smulders CE; Majoor-Krakauer D; Rozemuller AJ; Willemsen R; Pijnenburg YA; Heutink P; van Swieten JC
    Brain; 2012 Mar; 135(Pt 3):723-35. PubMed ID: 22300876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.
    Gomez-Deza J; Lee YB; Troakes C; Nolan M; Al-Sarraj S; Gallo JM; Shaw CE
    Acta Neuropathol Commun; 2015 Jun; 3():38. PubMed ID: 26108573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drosha inclusions are new components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion cases.
    Porta S; Kwong LK; Trojanowski JQ; Lee VM
    J Neuropathol Exp Neurol; 2015 Apr; 74(4):380-7. PubMed ID: 25756586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Emerging Role of DNA Damage in the Pathogenesis of the C9orf72 Repeat Expansion in Amyotrophic Lateral Sclerosis.
    Konopka A; Atkin JD
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30322030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for the C9ORF72 repeat expansion in a greek frontotemporal dementia cohort.
    Kartanou C; Karadima G; Koutsis G; Breza M; Papageorgiou SG; Paraskevas GP; Kapaki E; Panas M
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Feb; 19(1-2):152-154. PubMed ID: 29166782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features.
    Shaw MP; Higginbottom A; McGown A; Castelli LM; James E; Hautbergue GM; Shaw PJ; Ramesh TM
    Acta Neuropathol Commun; 2018 Nov; 6(1):125. PubMed ID: 30454072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD.
    Tang X; Toro A; T G S; Gao J; Chalk J; Oskarsson B; Zhang K
    Mol Neurodegener; 2020 Jun; 15(1):34. PubMed ID: 32513219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease Mechanisms of
    Gendron TF; Petrucelli L
    Cold Spring Harb Perspect Med; 2018 Apr; 8(4):. PubMed ID: 28130314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.
    DeJesus-Hernandez M; Mackenzie IR; Boeve BF; Boxer AL; Baker M; Rutherford NJ; Nicholson AM; Finch NA; Flynn H; Adamson J; Kouri N; Wojtas A; Sengdy P; Hsiung GY; Karydas A; Seeley WW; Josephs KA; Coppola G; Geschwind DH; Wszolek ZK; Feldman H; Knopman DS; Petersen RC; Miller BL; Dickson DW; Boylan KB; Graff-Radford NR; Rademakers R
    Neuron; 2011 Oct; 72(2):245-56. PubMed ID: 21944778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype.
    Rutherford NJ; Heckman MG; Dejesus-Hernandez M; Baker MC; Soto-Ortolaza AI; Rayaprolu S; Stewart H; Finger E; Volkening K; Seeley WW; Hatanpaa KJ; Lomen-Hoerth C; Kertesz A; Bigio EH; Lippa C; Knopman DS; Kretzschmar HA; Neumann M; Caselli RJ; White CL; Mackenzie IR; Petersen RC; Strong MJ; Miller BL; Boeve BF; Uitti RJ; Boylan KB; Wszolek ZK; Graff-Radford NR; Dickson DW; Ross OA; Rademakers R
    Neurobiol Aging; 2012 Dec; 33(12):2950.e5-7. PubMed ID: 22840558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. All in the Family: Repeats and ALS/FTD.
    Pattamatta A; Cleary JD; Ranum LPW
    Trends Neurosci; 2018 May; 41(5):247-250. PubMed ID: 29703376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit.
    Sattler R; Traynor BJ; Robertson J; Van Den Bosch L; Barmada SJ; Svendsen CN; Disney MD; Gendron TF; Wong PC; Turner MR; Boxer A; Babu S; Benatar M; Kurnellas M; Rohrer JD; Donnelly CJ; Bustos LM; Van Keuren-Jensen K; Dacks PA; Sabbagh MN;
    Neurol Ther; 2023 Dec; 12(6):1821-1843. PubMed ID: 37847372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of C9orf72 repeat expansions in patients with amyotrophic lateral sclerosis and frontotemporal dementia in mainland China.
    Jiao B; Tang B; Liu X; Yan X; Zhou L; Yang Y; Wang J; Xia K; Shen L
    Neurobiol Aging; 2014 Apr; 35(4):936.e19-22. PubMed ID: 24269022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia.
    Gagliardi D; Costamagna G; Taiana M; Andreoli L; Biella F; Bersani M; Bresolin N; Comi GP; Corti S
    Ageing Res Rev; 2020 Dec; 64():101172. PubMed ID: 32971256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway.
    Ciura S; Sellier C; Campanari ML; Charlet-Berguerand N; Kabashi E
    Autophagy; 2016 Aug; 12(8):1406-8. PubMed ID: 27245636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hexanucleotide Repeat Expansions in c9FTD/ALS and SCA36 Confer Selective Patterns of Neurodegeneration In Vivo.
    Todd TW; McEachin ZT; Chew J; Burch AR; Jansen-West K; Tong J; Yue M; Song Y; Castanedes-Casey M; Kurti A; Dunmore JH; Fryer JD; Zhang YJ; San Millan B; Teijeira Bautista S; Arias M; Dickson D; Gendron TF; Sobrido MJ; Disney MD; Bassell GJ; Rossoll W; Petrucelli L
    Cell Rep; 2020 May; 31(5):107616. PubMed ID: 32375043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The frequency of the C9orf72 expansion in a Brazilian population.
    Cintra VP; Bonadia LC; Andrade HMT; de Albuquerque M; Eusébio MF; de Oliveira DS; Claudino R; Gonçalves MVM; Teixeira AL; de Godoy Rousseff Prado L; de Souza LC; Dourado MET; Oliveira ASB; Tumas V; França MC; Marques W
    Neurobiol Aging; 2018 Jun; 66():179.e1-179.e4. PubMed ID: 29449030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and neuropathological features of ALS/FTD with TIA1 mutations.
    Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA
    Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 79.